Calluna Pharma
Marco Boorsma is an accomplished professional in the biotechnology and pharmaceuticals industry, currently serving as General Partner at Forbion since July 2007, with previous roles including Partner, Principal, and Senior Analyst. Marco holds the position of Chairman of the Board at Calluna Pharma since January 2024, after their leadership role at Oxitope Pharma ended with its merger into Calluna. Additionally, Marco serves as Board Director at multiple companies, including Sitala Bio, Rectify Pharma, VectorY, enGene, Inversago Pharma, and Escalier Biosciences, and has contributed significantly to the development of innovative therapeutics across various therapeutic areas. Marco obtained a PhD in Biotechnology from ETH Zürich and a BS in Molecular Biology from the University of Groningen.
This person is not in any teams
This person is not in any offices
Calluna Pharma
Our innovative therapeutic approach targets upstream amplifiers of disease offering potential treatments across a diverse array of therapeutic indications. Calluna Pharma is a clinical stage biotech company driven by a commitment to improve patient outcomes in diseases where existing treatments are sub-optimal. We believe in the power of immunology to push boundaries, challenge the status quo, and develop therapies that will make a real difference for people living with serious diseases.